Thursday, January 16, 2025

Viz.ai & Guardant Health Partner to Enhance Lung Cancer Care

Related stories

Neuromorphic Computing: Crafting the Future of Brain-Inspired Machines

In the progressively developing landscape of technology, the requirement...

Blaize & VSBLTY Partner on AI Hybrid Tech for Global Security

The joint development will provide AI-based computer vision solutions...

Atropos Health & xCures Use AI to Enhance Clinical Decisions & Care

The Partnership Will Enable Healthcare Providers To Leverage Actionable,...

ThoroughCare & CareCo AI Partner to Boost Care Efficiency

ThoroughCare announced that the company is entering a strategic...

Tempus One Launches GenAI for Research, Clinical Care

Tempus AI, Inc., a technology company leading the adoption...
spot_imgspot_img

Proposed collaboration aims to integrate cutting-edge AI and genomic insights to advance guideline-directed medical therapy

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, announced a proposed collaboration with Guardant Health, Inc., a leading precision oncology company, to address challenges in lung cancer care. The collaboration aims to help oncologists diagnose lung cancer earlier and make more informed treatment decisions to improve patient outcomes, reflecting the companies’ shared commitment to leveraging technology to close critical gaps in cancer care and streamline the patient journey.

“This collaboration represents a promising step forward in the fight against lung cancer and reflects our commitment to expanding Viz.ai’s impact in oncology,” said Dr. Chris Mansi, CEO and co-founder at Viz.ai. “Together, we have the opportunity to harness the power of AI and genomics to ensure patients receive timely, personalized, and effective care.”

Also Read: Atropos Health Boosts Precision Medicine with AI Models

Nearly 40% of lung cancer patients are estimated not to be receiving guideline-directed medical therapy.1 Delays in diagnosis, testing, and appropriate treatment increase the risk of lung cancer progression to advanced-stage disease and can contribute to higher mortality rates. The intent of the proposed collaboration between Viz.ai and Guardant is to address clinical practice gaps along the lung cancer patient journey by facilitating timely biomarker testing with the Guardant360® CDx liquid biopsy, thereby accelerating time to precision diagnosis and optimal treatment selection.

The Viz.ai One platform leverages machine learning algorithms to analyze data from imaging, the EHR and other tests and deliver real-time, actionable insights and automated assessments to accelerate diagnosis and treatment. Viz.ai acts as a safety net in 1,700 hospitals to automatically identify patients with disease and direct them to the right specialist and the right treatment.

Source: Businesswire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img